Carvykti™ (ciltacabtagene autoleucel) – New orphan drug approval
February 28, 2022 - Janssen announced the FDA approval of Carvykti (ciltacabtagene autoleucel), for the treatment of adult patients with relapsed or refractory multiple myeloma, after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Top